BR112013003064A2 - agente profilático ou terapêutico para a esteato-hepatite não alcoólica - Google Patents

agente profilático ou terapêutico para a esteato-hepatite não alcoólica

Info

Publication number
BR112013003064A2
BR112013003064A2 BR112013003064-0A BR112013003064A BR112013003064A2 BR 112013003064 A2 BR112013003064 A2 BR 112013003064A2 BR 112013003064 A BR112013003064 A BR 112013003064A BR 112013003064 A2 BR112013003064 A2 BR 112013003064A2
Authority
BR
Brazil
Prior art keywords
prophylactic
therapeutic agent
alcoholic steatohepatitis
agent
prevention
Prior art date
Application number
BR112013003064-0A
Other languages
English (en)
Japanese (ja)
Inventor
Matsui Toshiyuki
Ide Tomohiro
Tsunoda Masaki
Ogata Tomomi
Ito Minoru
Original Assignee
Kyorin Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co., Ltd. filed Critical Kyorin Pharmaceutical Co., Ltd.
Publication of BR112013003064A2 publication Critical patent/BR112013003064A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

agente profilático ou terapêutico para a esteato-hepatite não alcoólica. a presente invenção refere-se à provisão de um agente para a prevenção ou o tratamento de uma doença de fígado gorduroso, de preferência nafld, e com mais preferência nash. a presente invenção provê um agente para a prevenção ou o tratamento de uma doença de fígado gorduroso que contém ibudilast como um agente ativo.
BR112013003064-0A 2010-08-12 2011-08-11 agente profilático ou terapêutico para a esteato-hepatite não alcoólica BR112013003064A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010180656 2010-08-12
JP2010-180656 2010-08-12
PCT/JP2011/068344 WO2012020821A1 (ja) 2010-08-12 2011-08-11 非アルコール性脂肪肝炎の予防または治療剤

Publications (1)

Publication Number Publication Date
BR112013003064A2 true BR112013003064A2 (pt) 2018-01-30

Family

ID=45567781

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003064-0A BR112013003064A2 (pt) 2010-08-12 2011-08-11 agente profilático ou terapêutico para a esteato-hepatite não alcoólica

Country Status (11)

Country Link
US (1) US20130143913A1 (pt)
EP (1) EP2604607A4 (pt)
JP (1) JPWO2012020821A1 (pt)
KR (1) KR20130097722A (pt)
CN (1) CN103189374A (pt)
BR (1) BR112013003064A2 (pt)
CA (1) CA2808039A1 (pt)
MX (1) MX2013001583A (pt)
RU (1) RU2013110517A (pt)
TW (1) TW201211041A (pt)
WO (1) WO2012020821A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016085994A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Ibudilast and telmisartan for treating non-alcoholic fatty liver disease, non alcoholic steatohepatitis, and advanced non alcoholic steatohepatitis
CN105039513B (zh) * 2015-05-29 2018-12-28 广州市第一人民医院 用于非酒精性脂肪肝相关目的基因多态性检测方法及其引物，以及试剂盒
WO2017181317A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Treatment for nonalcoholic steatohepatitis and fibrosis
WO2018089495A1 (en) * 2016-11-08 2018-05-17 University Of Louisville Research Foundation, Inc. Encapsulation of phosphodiesterase inhibitors to treat alcoholic liver disease
CN111686239B (zh) * 2019-03-11 2021-12-24 中国科学院微生物研究所 抗真菌化合物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106054A1 (en) * 2002-12-03 2006-05-18 Michiaki Nagasawa Phosphodiesterase 10a inhibitors
WO2007030375A2 (en) * 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
WO2008124505A2 (en) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
JPWO2009154230A1 (ja) * 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
JP5443012B2 (ja) 2009-02-09 2014-03-19 タキロン株式会社 排水管路構造及びこれに用いる管継手

Also Published As

Publication number Publication date
CA2808039A1 (en) 2012-02-16
JPWO2012020821A1 (ja) 2013-10-28
EP2604607A4 (en) 2014-01-01
EP2604607A1 (en) 2013-06-19
WO2012020821A1 (ja) 2012-02-16
KR20130097722A (ko) 2013-09-03
CN103189374A (zh) 2013-07-03
MX2013001583A (es) 2013-03-21
US20130143913A1 (en) 2013-06-06
RU2013110517A (ru) 2014-09-20
TW201211041A (en) 2012-03-16

Similar Documents

Publication Publication Date Title
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BR112018007857A2 (pt) combinações de gemcabene para o tratamento de doença cardiovascular
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BR112014010291A2 (pt) composições de lipossoma combinacionais para terapia de câncer
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
BR112012024349A2 (pt) métodos de tratamento de carcinoma hepatocelular
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
BR112013022789A2 (pt) composições farmacêuticas que compreendem metformina e um inibidor dpp-4 ou um inibidor sglt-2
BR112015012197A2 (pt) terapia de combinação
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112013005492A2 (pt) dispositivos de implante capilares
MX347471B (es) Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112016001446A8 (pt) composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112013010556A2 (pt) métodos e composições adequadas para a promoção de uma pele saudável
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
BR112015018270A2 (pt) composições que compreendem 15-ohepa e métodos de uso das mesmas
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112015004465A2 (pt) sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]